New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTJAH, WWAV, RGP, TCO, PRGO, AGN, ACMP, BIN, TEVA, SGNT, MYL, COTY, NMBL, EGHT, TEX, O, CQP, ACRX, AKRX, ANIP, ACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ANI Pharmaceuticals (ANIP) initiated with a Buy at Roth Capital... AcelRx (ACRX) initiated with an Outperform at RBC Capital... Actavis (ACT) initiated with an Outperform at RBC Capital... Akorn (AKRX) initiated with an Outperform at RBC Capital... Allergan (AGN) initiated with an Outperform at RBC Capital... Cheniere Energy Partners (CQP) initiated with an Outperform at Credit Suisse... Mylan (MYL) initiated with an Outperform at RBC Capital... Perrigo (PRGO) initiated with a Top Pick at RBC Capital... Realty Income (O) initiated with an Outperform at Oppenheimer... Sagent Pharmaceuticals (SGNT) initiated with an Underperform at RBC Capital... Taubman Centers (TCO) initiated with a Perform at Oppenheimer... Terex (TEX) initiated with a Hold at Jefferies... Teva (TEVA) initiated with a Sector Perform at RBC Capital... Regency Energy Partners (RGP) reinstated with an Outperform at Credit Suisse... 8x8, Inc. (EGHT) initiated with a Buy at Needham... Progressive Waste (BIN) initiated with an Underperform at Macquarie... WhiteWave Foods (WWAV) reinstated with an Overweight at JPMorgan... Nimble Storage (NMBL) initiated with a Buy at Stifel... Access Midstream (ACMP) coverage assumed with an Outperform at Credit Suisse... Jarden (JAH) initiated with an Outperform at RBC Capital... Coty (COTY) initiated with a Sector Perform at RBC Capital.
News For ANIP;ACRX;ACT;AKRX;AGN;CQP;MYL;PRGO;O;SGNT;TCO;TEX;TEVA;RGP;EGHT;BIN;WWAV;NMBL;ACMP;JAH;COTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 25, 2015
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTPRGO, MYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
12:31 EDTNMBLNimble Storage technical notes ahead of results
Subscribe for More Information
11:27 EDTTEVA, PRGO, MYLTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
09:59 EDTCOTYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: SunEdison (SUNE) downgraded to Neutral from Buy at UBS... Green Bancorp (GNBC) downgraded to Neutral from Buy at SunTrust... BOK Financial (BOKF) downgraded to Neutral from Buy at SunTrust... AGL Resources (GAS) downgraded to Hold from Buy at Argus... Coty (COTY) downgraded to Neutral at JPMorgan.
08:47 EDTCOTYCoty downgraded to Neutral at JPMorgan
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
August 24, 2015
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
08:14 EDTTCOTaubman Centers upgraded on growth outlook, valuation at Oppenheimer
As noted earlier, Oppenheimer upgraded Taubman to Outperform from Perform. The firm thinks that more bad news about the company's developments is unlikely to surface, since some projects have opened and others have progressed significantly. It believes that the stock provides "an attractive combination of growth and value." Target $85.
06:38 EDTTCOTaubman Centers upgraded to Outperform from Perform at Oppenheimer
August 21, 2015
15:22 EDTPRGO, MYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTPRGO, MYLMylan to host special shareholder meeting
Subscribe for More Information
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
14:39 EDTNMBLEarnings Watch: Hewlett-Packard reports ahead of company split
Subscribe for More Information
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
August 19, 2015
12:53 EDTNMBLEarnings Watch: Analysts mostly bearish on NetApp ahead of Q1 earnings
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use